MicroRNA master regulator of hematopoiesis may also hold the key to B-cell lymphoma pathogenesis and therapy.

Lawrie, CH.

Translational Cancer Research. 2016; 5: 913-915. FI: 1,167 (Q4).

Sensitivity Limit of Nanoparticle Biosensors in the Discrimination of Single Nucleotide Polymorphism.

Sanroman-Iglesias M, Lawrie CH, Schafer T, Grzelczak M, Liz-Marzan LM.

Acs Sensors. 2016; 1: 1110-1116. FI: 0 (Q4).

Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.

Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, Navajas A, Echebarria-Barona A, Garcia-Miguel P, Garcia de Andoin N, Lobo C, Guerra-Merino I, Martin-Guerrero I, Garcia-Orad A.

Pharmacogenomics. 2016; 17: 731-741. FI: 2,35 (Q3).

Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile.

Gonzalez-Martin A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, Andres R, Alvarez I, Aramenda JM, Ayala de la Pena F, Barnadas A, Batista N, Calvo L, Galve E, Garcia-Palomo A, Garcia-Saenz, JA, de la Haba J, Lopez R, Lopez-Vivanco G, Martinez-Janez N, Martinez de Duenas E, Plazaola A, Rodriguez-Lescure A, Ruiz M, Sanchez-Rovira P, Santaballa A,Segui MA, Tusquets I, Zamora P, Martin M.

Current Cancer Drug Targets. 2016; 16: 415-428. FI: 2,992 (Q3).

Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial.

Martínez E, Martínez M, Rico M, Hernández B, Casas F, Viñolas N, Pérez-Casas A, Dómine M, Mínguez J.

Oncotargets And Therapy. 2016; 9: 1057-1066. FI: 1,653 (Q3).

Catalysis by multifunctional polyelectrolyte capsules.

Hussain S, Zajif Z, Mikhail VH, Irshad P, Wolfgang J, Carregal-Romero S.

Rsc Advances. 2016; 6: 81569-81577. FI: 3,108 (Q2).

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV.

European Journal Of Haematology. 2016; 96: 532-540. FI: 2,653 (Q2).

Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.

Pérez R, Durán MS, Mayans J, Soler A, Castillo I, Jurado M, Ribas P, Menchaca Echevarria MC, Hernandez MT, Lopez MD, Echeveste A, Bailen Garcia A, Lopez S, Baquero J, Ramirez G.

European Journal Of Haematology. 2016; 96: 417-424. FI: 2,653 (Q2).

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.

Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D.

Bmc Cancer. 2016; 16: 135-135. FI: 3,288 (Q2).

Why some tumours trigger neovascularisation and others don’t: the story thus far.

Adighibe O, Leek RD, Fernandez-Mercado M, Hu J, Snell C, Gatter KC, Harris AL, Pezzella F.

Chinese Journal Of Cancer. 2016; 35: 18-18. FI: 4,111 (Q2).